DASATINIB, a drug commonly
used to treat leukaemia, is showing
promise as a treatment that could
slow the muscle-wasting condition,
Duschenne Muscular Dystrophy.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 07 Jan 16 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jan 16
CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).